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Editorial
Clinical trials in rheumatology. Does one size fit all?
Identifying the three patient population sets might be the first step
The introduction of biologic agents has allowed great
strides to be made in the management of patients with
autoimmune rheumatic diseases (ARDs) in the past few
decades. We can now effectively deal with various
facets of the immune response and the inflammatory cas-
cade that are responsible for the clinical features of ARDs.
Examples of improvements for patients are numerous.
The prevalence of extra-articular involvement and the se-
verity of disease-related damage and disability have
reduced in RA. ANCA-associated small-vessel vasculi-
tides (AAVs), once conveying a prognosis similar to ag-
gressive cancer, are now curable in the vast majority of
patients. These results have been made possible by a
convergence of interests between practising physicians
and medical industries and by a synthetic one-size-fits-
all approach, with patients grouped into few inclusive
nosologic entities.
The abnormal presence of microbial components in
biologic specimens directs diagnosis, classification and
therapy of infectious diseases, whereas the identification
of the impact on gene function of specific mutations is
the key for classification and, when feasible, for the man-
agement of monogenic diseases. Biology of the can-
cerstroma complex, which is defined by tissue of
origin, histological features and molecular markers, plays
this role in oncology. ARDs include heterogeneous syn-
dromes for which nosology (i.e. the codification of dis-
eases), diagnosis (i.e. synthetizing patient features into a
specific disease previously defined) and the classification
of disease subsets are not uniquely defined and are con-
tinuously adapted to meet the current medical knowledge.
Indeed, the definition of vasculitides has been recently
updated [1], and criteria for diagnosis and/or classification
(used here with the meaning of definitive diagnosis spe-
cific enough for enrolment in clinical studies) are repeat-
edly refined using the opinion of experts as terms of
reference [2].
A synthetic, one-size-fits-all approach is in general ideal
for all conditions that depend on single mechanisms to
be pathogenic, shared by all or by most patients with that
diagnosis. Even if environmental cues and genetically deter-
mined predispositions modulate the eventual manifestations
of a disease, identifying and targeting single, non-redundant
events would provide effective therapeutic strategies. Gene
therapy or bone marrow transplantation for monogenic dis-
eases or haemoglobinopathies are examples of this ap-
proach. Unfortunately, single pathogenic mechanisms for
most ARDs are missing. At present, we lack a clear view
of most events that cause the clinical and biological
manifestations of ARDs and, specifically, we ignore the pre-
cise hierarchy among disease-associated events.
Thus, a reasoning that focuses on the characteristics
shared by groups of patients is used for nosography
and diagnosis of ARDs. Differences are usually neglected,
resulting in substantial heterogeneity in patients with the
same diagnostic tag. Translational and clinical research
studies use existing nosologic entities as a backbone for
patient enrolment, further strengthening the current nos-
ology even when it is not fully satisfactory.
Reducing the complexity of patient phenotypes into a
limited number of nosological entities simplifies the life of
the physician, providing a reassuring logical framework,
facilitating the diagnostic process with clear classification/
diagnostic criteria, and highlighting evidence-based man-
agement, with important legal implications. Moreover, the
reductionist grouping approach ensures that medical
industries have a greater number of potential customers.
However, even such a successful approach has limitations.
Trials studying new agents for ARDs comprise at least
three population sets of patients: those responding to con-
ventional treatments, in which limited additional benefit can
be expected; those responding substantially better to
the new medication; and those not responding either to
the conventional or to the new regimen. As treatments
become more and more effective and the number of
patients not reaching a specific outcome with standard
therapy progressively decreases, the average advantage
of novel therapies in large and heterogeneous groups of
patients cannot but diminish while the number needed to
treat increases. Thus, trials need progressively to increase
their sample size. We believe that this approach, although
useful for clinicians and possibly lucrative for companies,
might be inefficient and involve greater expenses for trials
and for clinical management. The majority of patients
receiving a novel, costly medication on the basis of new
evidence and recommendation may not genuinely benefit
or need it.
Could alternative strategies be developed?
Characterization of the above-mentioned three population
sets, focusing on patients’ distinctive features rather than
on similarities, might be a first step. For example, it is
accepted that the expression of serological disease mar-
kers, autoantibodies in particular, can be used to identify
subsets of patients that are relatively homogeneous in
terms of clinical features or prognosis. This is, for ex-
ample, the case of AAVs or of RA. The presence of
ANCA in patients with eosinophilic granulomatosis with
polyangiitis is associated with more extensive vasculitic
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manifestations, and ANCA antigen specificity is more clo-
sely associated with disease features, genetic predispos-
ition and prognosis than clinical diagnosis [3, 4]. RF and
ACPAs positivity is associated with severity and with
some clinical features of RA, including the presence of
extra-articular manifestations and the accelerated erosive
involvement (e.g. see Aletaha et al. [5]).
Serological disease markers can be used to identify
relatively homogeneous subsets of patients, which has
an impact on the response to treatments. ANCA specifi-
city represents an independent factor predicting relapses
in patients with AAVs, whereas RF might predict the re-
sponse to rituximab and tocilizumab in patients with RA
[6]. ANCAs, ACPAs and RF are not only disease markers
but also players in the disease pathogenesis. This might
be relevant for their ability to identify patients who re-
spond (or fail to respond) to treatments. In general, we
believe that the identification of biomarkers that are asso-
ciated with the pathogenesis of ARDs could lead to iden-
tification within patients taking the same diagnostic tag
subsets who are more likely to benefit from novel treat-
ments. Expression or titres of soluble molecules, molecu-
lar and functional imaging studies, and morphological or
biomolecular tissues evaluations could all, in principle,
contribute to split patients into more homogeneous
groups.
This could be a priority in the research agenda for the
next few years; on the one hand, shedding light on the
heterogeneity within existing nosologic entities, possibly
resulting in the identification of a plurality of diseases
among those that are inscribed in currently coded nos-
ology, and on the other hand, making smaller and cheaper
studies possible and informative.
The research funded by the medical industry cannot be
asked to work in this direction. Rather, it is the duty of
academic research to overcome the one-size-fits-all ap-
proach. Sponsored research may choose to follow new
findings later. Academic research, which has the aims
not only to improve knowledge and medical manage-
ment of rheumatic patients but also to increase the effi-
ciency of the whole system (by reducing expenses for
drug administration and trial implementation), needs
economic support. This investment by the National
Health Systems will be rewarded with good interest for
the community, making the development of treatments at
a lower cost possible and enabling more effective patient
care.
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